Literature summary for 3.4.17.20 extracted from

Folkeringa, N.; Coppens, M.; Veeger, N.J.; Bom, V.J.; Middeldorp, S.; Hamulyak, K.; Prins, M.H.; Bueller, H.R.; van der Meer, J.
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels (2008), Thromb. Haemost., 100, 38-44.

Search for more literature for 3.4.17.20

Application

Application	Comment	Organism
medicine	the absolute risk of venous and arterial thromboembolism in subjects with high TAFI levels versus subjects with normal levels, and the contribution of other concomitant thrombophilic defects is assessed. Relatives from four identical cohort studies in families with either deficiencies of antithrombin, protein C or protein S, prothrombin 20210A, high factor VIII levels, or hyperhomocysteinemia are pooled. Only high factor VIII levels are associated with an increased risk of venous and arterial thrombosis, independently of TAFI levels. None of these concomitant defects shows interaction with high TAFI levels. High TAFI levels are not associated with an increased risk of venous and arterial thromboembolism in thrombophilic families	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
blood plasma	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
TAFI	-	Homo sapiens
thrombin-activatable fibrinolysis inhibitor	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)